GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Silk Road Medical Inc (FRA:2OW) » Definitions » EPS (Diluted)

Silk Road Medical (FRA:2OW) EPS (Diluted) : €-1.28 (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Silk Road Medical EPS (Diluted)?

Silk Road Medical's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was €-0.33. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.28.

Silk Road Medical's EPS (Basic) for the three months ended in Mar. 2024 was €-0.33. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.28.

Silk Road Medical's EPS without NRI for the three months ended in Mar. 2024 was €-0.33. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.28.

During the past 3 years, the average EPS without NRIGrowth Rate was -0.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 2.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Silk Road Medical's highest 3-Year average EPS without NRI Growth Rate was 12.40% per year. The lowest was -20.40% per year. And the median was -2.00% per year.


Silk Road Medical EPS (Diluted) Historical Data

The historical data trend for Silk Road Medical's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silk Road Medical EPS (Diluted) Chart

Silk Road Medical Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial -2.05 -1.18 -1.27 -1.45 -1.32

Silk Road Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.40 -0.32 -0.31 -0.31 -0.33

Competitive Comparison of Silk Road Medical's EPS (Diluted)

For the Medical Devices subindustry, Silk Road Medical's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silk Road Medical's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Silk Road Medical's PE Ratio distribution charts can be found below:

* The bar in red indicates where Silk Road Medical's PE Ratio falls into.



Silk Road Medical EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Silk Road Medical's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-51.116-0)/38.804
=-1.32

Silk Road Medical's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-13.005-0)/39.261
=-0.33

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Silk Road Medical  (FRA:2OW) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Silk Road Medical EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Silk Road Medical's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Silk Road Medical (FRA:2OW) Business Description

Traded in Other Exchanges
Address
1213 Innsbruck Drive, Sunnyvale, CA, USA, 94089
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.

Silk Road Medical (FRA:2OW) Headlines

No Headlines